Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC). The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
| Business Activity | PASS |
| Debt Ratio (0.00%) | PASS |
| Cash Ratio (0.40%) | FAIL |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2023-11-14 | -0.40 | -0.33 | +16.9% |
| 2023-08-14 | -0.38 | -0.48 | -26.9% |
| 2023-05-11 | -0.43 | -0.50 | -16.4% |
| 2023-03-08 | -0.51 | -0.58 | -14.8% |
| 2022-11-09 | -0.50 | -0.60 | -19.3% |
| 2022-08-09 | -0.51 | -0.54 | -6.7% |
| 2022-05-16 | -0.60 | -0.58 | +2.9% |
| 2022-03-10 | -0.76 | -0.64 | +15.8% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | -$1.6M | -$1.7M | — | -$1.7M | -0.01 |
| 2025-12-31 | — | $153.1M | -$1.5M | — | -$1.5M | — |
| 2025-09-30 | — | -$1.4M | -$1.4M | — | -$1.4M | -0.01 |
| 2025-06-30 | — | -$1.1M | -$1.1M | — | -$1.1M | — |
| 2025-03-31 | — | -$1.6M | -$2.0M | — | -$2.0M | -0.01 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-04-07 | CHANG NANCY T | Director and Beneficial Owner of more than 10% of a Class of Security | 1,180,611 | -- |
| 2026-04-07 | FRIEDMAN MICHAEL R | Director | 5,336,870 | -- |
| 2025-11-20 | SORENSEN MELINDA | Chief Executive Officer | 70,000 | $1.4K |
| 2024-12-30 | CHANG NANCY T | Director and Beneficial Owner of more than 10% of a Class of Security | 7,644,932 | $206.4K |
| 2024-08-16 | SORENSEN J. MEL | Chief Executive Officer | 67,015 | $4.8K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Ascentis Independent Advisors | 93.0 | $9.0 | — |
$14.9M
1.89
2.642
1.16
0.1%
3
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| AVNS | 0.279 |
| GAINZ | 0.234 |
| ARAI | 0.233 |
| 4330.SR | 0.192 |
| HBGRY | 0.183 |
| Ticker | Correlation |
|---|---|
| RENO | -0.214 |
| XPEL | -0.189 |
| MCLDF | -0.135 |
| ADERY | -0.120 |
| KVYO | -0.118 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.